Cabotegravir

Approved for adults only.

ARV U.S. Brand Name

Vocabria

ARV Abbreviation(s)

CAB

U.S. FDA Label

Cabotegravir Label (Package insert)

ARV Class

Integrase inhibitors

First U.S. Approval

January 21, 2021

U.S. Manufacturer

ViiV Healthcare

Formulations

Strength	Formulation	Image	Description	Boosted
30 mg	Tablet	X	Oval white table with "SV CTV" imprint	No
400 mg	Extended-release injectable suspension	X	kit label for Cabenuva	No
600 mg	Extended-release injectable suspension	X	kit label for cabenuva (600 mg CAB, 900 mg RPV)	No

Generic Available?

Other Reference Links

Clinical Info HIV Drug Database

National HIV Curriculum

Adult dosing

30 mg once daily for at least 28 days Tablet

Coadminister with 25 mg rilpivirine once daily for initiation period.

300 mg (3 mL) intramuscular (gluteal) initiation injection one-time dosing (after lead-in) Extended-release injectable suspension

Coadminister with 900 mg rilpivirine IM injection (Cabenuva is supplied as a co-packaged kit)

400 mg (2 mL) monthly from month 3 onward Extended-release injectable suspension

Coadminister with 600 mg rilpivirine IM injection (Cabenuva is supplied as a co-packaged kit)

Pediatric dosing

FDCs

Cabotegravir / Rilpivirine IM

Assistance Programs

ViiV Connect

Displaying 1 - 19 of 19

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Cabotegravir RIF 343	Red: Avoid combination	Do not coadminister: Reduced levels of CAB	Potential decrease in antiretroviral efficacy	Cmax decreased 6%, AUC decreased 59%, Cmin decreased 50%	600 mg once daily	Not studied	Contraindicated. Use alternative agents.
Cabotegravir Griseofulvin 342	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir St. John's Wort (Hypericum perforatum) 341	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir RPT 340	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Primidone 339	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Phenytoin 338	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Phenobarbital 337	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Oxcarbazepine 336	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Eslicarbazepine 335	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Enzalutamide 334	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir CBZ 333	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir ETR 332	Green: Administer standard doses	Administer standard doses		Cmax increased 4%, AUC increased 1%	200 mg once daily	Not studied
Cabotegravir Midazolam 331	Green: Administer standard doses	Administer standard doses		Not studied	3mg	Cmax increased 9%, AUC increased 10%
Cabotegravir LNG 330	Green: Administer standard doses	Administer standard doses		Not studied	0.15 mg once daily	Cmax increased 5%, AUC increased 12%, Cmin increased 7%
Cabotegravir EE/NGM 329	Green: Administer standard doses	Administer standard doses		Not studied	0.03mg once daily	Cmax decreased 8%, AUC increased 2%
Cabotegravir RPV 328	Green: Administer standard doses	Administer standard doses		Cmax increased 5%, AUC increased 12%, Cmin increased 14%	25 mg once daily	Cmax decreased 4%, AUC decreased 1%, Cmin decreased 8%
Cabotegravir RFB 327	Green: Administer standard doses	Administer standard doses		Cmax decreased 17%, AUC decreased 23%, Cmin decreased 26%	300 mg once daily	Not studied
Cabotegravir Aluminum and magnesium hydroxide antacid 326	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of cabotegravir		Not studied		Not studied	Administer antacids by at least 2 hours before or 4 hours after oral CAB
Cabotegravir

Subscribe to Cabotegravir